News & Events : Press Releases
August 12, 2014
FORMA Therapeutics and Paradigm Announce Molecular Profiling Collaboration for Drug Candidates
Strategic partnership to characterize genomic predictors of response for FORMA’s preclinical cancer therapies, accelerating clinical decision making
ANN ARBOR, Mich. & WATERTOWN, Mass. – August 12, 2014 – Paradigm and FORMA Therapeutics, Inc. announced today a multi-year partnership to identify predictive response markers and measure pharmacodynamic activity for two of FORMA’s advanced preclinical candidates. Working with Paradigm to assess the potential of molecular markers to predict clinical outcomes will help FORMA accelerate clinical decisions and optimize its new medicines for patients.
Steven Tregay, Ph.D., President and CEO, FORMA Therapeutics stated, “FORMA’s strategy is to pair a thorough understanding of the molecular drivers of tumor growth and survival with our capability to discover ultra-selective drugs against these qualified targets. Our collaboration with Paradigm enables us to efficiently match our drugs with high quality molecular assays to realize a personalized approach to cancer drug development.”
“FORMA has a strong oncology pipeline with many exciting therapeutic candidates,” said Robert Penny, M.D., Ph.D., Chief Executive Officer, Paradigm. “We are excited to be working with FORMA to provide greater insights into their programs and trials with our unique expertise and ability to provide genomic information that can impact clinical treatment decisions. Together, we expect to enable a more individualized, targeted approach to cancer drug development and clinical trials.”
Paradigm is a non-profit molecular information corporation established to bring cutting-edge diagnostics to cancer patients and clinical trials by providing information about the genomic makeup of the patient’s cancer and potential therapies based on the specific characterization of the patient’s tumor that can impact the patient’s course of treatment. Paradigm’s Next-Generation Sequencing based diagnostic test PCDx provides oncologists and patients with more precise information about the specific cancer pathways in the patient and associations between the pathways and the specific drugs available that can affect the cancer to allow for more effective decision-making. The test is driven by supporting data and literature and provides more choices for patient care than currently available on the market. For more information visit www.paradigmdx.org.
FORMA Therapeutics' scientists are passionate about discovering and developing medicines that will make a difference in oncology and other genetically driven therapeutic areas. The company's drug discovery engine drives screening and structure-based approaches across broad families of targets involved in tumor metabolism, epigenetics, protein homeostasis and protein-protein interactions. Deep biological insight across targets is combined with the company's chemistry expertise and integrated with a world class network of academic investigators, clinical experts and corporate partners to rapidly direct the creation of high quality, innovative drug candidates.
FORMA is headquartered in Watertown, MA near the epicenter of the Cambridge Life Sciences cluster, with additional chemistry operations in Branford, CT.
Join our conversation on Twitter @FORMAInc.